Bullous Pemphigoid - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Bullous Pemphigoid - Pipeline Review, H1 2018’, provides an overview of the Bullous Pemphigoid pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bullous Pemphigoid, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid

- The report reviews pipeline therapeutics for Bullous Pemphigoid by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Bullous Pemphigoid therapeutics and enlists all their major and minor projects

- The report assesses Bullous Pemphigoid therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Bullous Pemphigoid

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bullous Pemphigoid

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bullous Pemphigoid pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akari Therapeutics Plc

Bioverativ Inc

Eli Lilly and Co

iCo Therapeutics Inc

Immungenetics AG

TxCell SA

Akari Therapeutics Plc

Bioverativ Inc

Eli Lilly and Co

iCo Therapeutics Inc

Immungenetics AG

TxCell SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bullous Pemphigoid – Overview

Bullous Pemphigoid – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bullous Pemphigoid – Overview

Bullous Pemphigoid – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bullous Pemphigoid – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bullous Pemphigoid – Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Bioverativ Inc

Eli Lilly and Co

iCo Therapeutics Inc

Immungenetics AG

TxCell SA

Bullous Pemphigoid – Drug Profiles

AC-203 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bertilimumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIVV-009 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl fumarate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENTX-BP – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixekizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bullous Pemphigoid – Dormant Projects

Bullous Pemphigoid – Product Development Milestones

Featured News & Press Releases

May 15, 2018: Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Mar 12, 2018: Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium

Sep 27, 2017: Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Aug 28, 2017: Immune Pharmaceuticals Provides update on bertilimumab

Feb 28, 2017: Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid

Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States

Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid

Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid

Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine

Jun 25, 2015: Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid

Mar 31, 2015: Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab

Feb 05, 2015: Immune Pharmaceuticals To Present At The BIO CEO & Investor Conference

Dec 09, 2014: CEO Dr. Daniel Teper of Immune Pharmaceuticals to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014

Jul 30, 2014: Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bullous Pemphigoid, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development ...

List of Tables

Number of Products under Development for Bullous Pemphigoid, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bullous Pemphigoid – Pipeline by Akari Therapeutics Plc, H1 2018

Bullous Pemphigoid – Pipeline by Bioverativ Inc, H1 2018

Bullous Pemphigoid – Pipeline by Eli Lilly and Co, H1 2018

Bullous Pemphigoid – Pipeline by iCo Therapeutics Inc, H1 2018

Bullous Pemphigoid – Pipeline by Immungenetics AG, H1 2018

Bullous Pemphigoid – Pipeline by TxCell SA, H1 2018

Bullous Pemphigoid – Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Bullous Pemphigoid, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Bullous Pemphigoid, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports